Financial constraints versus public desire for more-generous healthcare create a difficult dilemma for countries globally. As each market strives to manage its prescription drug market, highly specific market access requirements and challenges abound for drugmakers. Innovative developers must engage with payers much earlier in the product development cycle in order to optimize trial design to satisfy specific MA and payer requirements on demonstrating innovation (e.g. selecting the appropriate comparator, targeting the correct/local patient population, gathering the most compelling head-to-head). By exploring how pricing and reimbursement (P&R) decisions are made in many major and developing markets around the world, we have developed a Country Archetypes model that identifies similarities among payer requirements, and, vitally, determines where product value messaging can be leveraged to optimize market access strategy. Data on payer type and drug review processes, payer fragmentation, percentage of individuals covered by a health insurance system, size of the pharmaceutical market, percentage of government and individuals in healthcare spending, and use as a reference country for other nations were collected for 27 of the largest pharmaceutical markets in the world. Considerations around free pricing, health technology assessment, and review of pharmacoeconomic and outcomes research data rules were made, and further segmentations on decision impact, size of reimbursable market, out-of-pocket costs, role of health insurance and market fragmentation applied. Ultimately, from the 27 nations examined, six groups emerged, each comprising countries with commonalities across all measures, albeit distinct profiles that affect P&R: Accountants, Pragmatists, Evidence seekers, Deal-makers, Ceiling setters, and Independents. Our Country Archetype model is intended to help multinational pharmaceutical companies prepare for local reimbursement evaluations, and pinpoint where decision-makers can be found. With classifications based on the most important set of reimbursement criteria necessary to attain favorable access in each market, the keys to access can be found and turned. Kazakhstan is an upper-middle-income country with per capita GDP of nearly US$13 thousand in 2013. Kazakh's public healthcare system -UNHS (Unified National Health System) -aims to deliver healthcare coverage to the whole population. Despite this objective, only two thirds of interventions (on average) in UNHS were fully covered by public funding, while the remaining were funded by patients through either private health schemes or out-of pocket payments. Finding better ways to manage the use and cost of health technology is a high priority for Kazakh policy makers. As health policy makers face increasing pressure from the public to make explicit determinations about how and which technologies will be covered within the state guaranteed benefits package, the profile and scrutiny of HTA activity has, consequently, also increased. Even though there has been a rapid growth of HTA activities, HTA has not been developed as much as expected. There are several possible reasons why the MoH did not develop the strategy adopting HTA. First, comprehensive evaluation through HTA would make clear the failure of health policy previously implemented. Second, the MoH still relied on the traditional consensus method based on opinion or experience, which favors incremental and marginal changes, rather than a drastic reform. Third, there has been a power game of politics between innovative and conservative groups in the MoH. The Kazakh health care system needs HTA to be constructive to enable decision makers to make informed decisions with regard to the adoption of health technology. The development and promotion of clear criteria for selection of HTA topics is, therefore, essential to promote the efficient use of HTA information for decision making with respect to setting ultimate goals for HTA. Despite the average Indian patient becoming more knowledgeable with regards to his/her health, disease and treatment options, many Indian physicians still depend heavily on disease-related outcome measures to take health-care related decisions, and give minimal importance to patient-reported outcomes (PROs) pertaining to the effect of the healthcare interventions on the patient's well-being. This trend is also seen in clinical trials (CTs) in India where PROs, if used, are only secondary to diseaserelated outcomes. As on today, there are no commendable patient-centered outcome researches (PCORs) happening in India. With the arrival of PCOR Institute (PCORI) in the US, PROs are now getting the attention that they deserve; however, in India the concept is yet to catch up. PROs have a significant role in CTs, such as determination of patient eligibility, determination of patient compliance, as a study endpoint, determination of health-related quality of life (HRQoL), and assessing economic burden and indirect impact of disease and treatment. Implementation of regular PROs assessment in clinical trials can help in determining the negative effects of therapy, comparing two standard therapies having similar survival outcomes, finding out whether a new therapy is preferable to standard therapy, determining whether a therapeutic regimen is better than supportive care only, when survival time is short, and making the communication easier in clinical practice. Improved design and proper implementation of PROs in clinical trials (CTs) are necessary to provide high quality evidence to synthesize clinical practice guidelines. Implementation of PROs in CTs should be made mandatory for pharmaceutical companies to prove their label claims, especially in a country like India where the generic market is strong and widespread. Also, data obtained from PROs in CTs should be made the source document for making healthrelated decisions at all levels in India.
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PHP187 THe PillArs of CosT-effeCTiveness: A PrACTiCAl guideline for new TeCHnology CosT-effeCTive deCision-MAking
CalderÓn M. R. Novartis Pharmaceuticals, Guatemala, Guatemala BACKGROUND: The critical importance and use of health technology assessment in health care decisions towards improved health is practically nonexistent in many Central American and Caribbean countries. A culture with a health economics mindset that enhances access to new technologies is needed, one that increases the knowledge and application of economic evaluation amongst health stakeholders to make cost-effective decisions that improve health. OBjeCtives: In general, to find new ways to make new drugs and technologies available to patients, healthcare providers, governments and society as a whole. Specifically, to develop a practical guideline for the pharmaceutical and healthcare industries to make new technologies available to patients in resource-limited settings. MethODs: A needs assessment was conducted amongst key internal (pharmaceutical industry) and external stakeholders (public, private and non-profit institutions) in Central America and the Caribbean to gain insight into their decision-making basis and behaviors regarding new technology acquisition. A literature review of lessons learned and best practices around the world complemented the information collected from local stakeholders. ResUlts: A pivotal concept was created and coined as Pillars of Cost-Effectiveness. This concept advocates for three types of "effectiveness" comprising each three types of strategic considerations as follows: 1. Clinical Effectiveness: safety, efficacy and quality, 2. Medical Access Effectiveness: valueadded services, impact information dissemination and managed-entry agreements, and 3. Economic Effectiveness: burden of disease data, cost-effectiveness evidence and budget impact analysis. CONClUsiON: The Pillars of Cost-Effectiveness may serve as the "New Technology Cost-Effectiveness Checklist" to make evidence-based decisions in resource-limited settings. In turn, it may become the tool to assess and assure the universal goals of patients, providers, payers and policy-makers to (1) get the best drug and technology quality at the lowest cost and with reasonable access, and (2) enhance healthcare partnerships and solutions towards improved individual and population health outcomes. 
PHP188 develoPing HosPiTAl bAsed HTA for egyPTiAn CAnCer PATienTs
BACKGROUND:
Cancer is an increasing problem in developing countries. It ranks as the fourth leading cause of death in the eastern Mediterranean region and is one of the leading causes of death in the world. Although, in developing countries, incidence of cancer is still below that in the developed ones, they are expected to experience an increase in the burden of cancer, which if added to the more limited resources available, requires immediate intervention. Multiple projects had been initiated, but facing technical and other problems related to resources and equity leads them to be ineffective and inefficient. Objectives: Developing the nucleus for numerous Oncology Hospital-Based HTA (HB HTA) units as a tool for evidence based decision making and better utilization of resources to reach for a highly performing healthcare system. MethODs/RespONsiBilities: Decentralized HB HTA emerges from the need to take tailored healthcare decisions in a short period of time. These decisions should make use of local intrinsic data, providing solutions that are compatible with the hospital's values and priorities. Generally, responsibilities include receiving requests (according to certain technical, medical, clinical, economic, and social aspects) from Healthcare Practitioners and/or decision makers in relation to the adoption of certain technology/intervention. This unit then aggregates all the available data (from primary and secondary sources), synchronize and analyze them appropriately, resulting in site-relevant clinical and economic final assessments. DisCUssiON: A single university (department) experience as a nucleus for HB HTA is centered on the three main interest of a university hospital: Research, Education and Clinical practice. It depends on the presence of: 1-A chemotherapy independent unit which can provide standardized regimens based on the HTA-based decisions, 2-Well-developed oncology electronic medical record to insure standardized data collection and rapid communication between different departments, 3-an E-learning program, and 4-a clinical research unit. The Medicare Modernization Act of 2003 requires prescription drug plans to provide medication therapy management services to eligible Part D beneficiaries. In 2010, in an attempt to increase consistency among programs, the Centers for Medicare and Medicaid Services (CMS) expanded the regulatory requirements associated with medication therapy management (MTM). After evaluating the outcomes of MTM since its implementation in 2006, CMS concluded that the program has fallen short of expectations. On implementation of MTM, CMS projected that 25 percent of Medicare beneficiaries would qualify for MTM based on the proposed eligibility criteria. In reality, the percent of MTM eligible beneficiaries has fallen far below that approximation. Among members who meet eligibility criteria, MTM completion rates remain around 20 percent, on average. CMS also notes that certain racial and ethnic disparities continue to exist in MTM eligibility. Specifically, African American and Hispanic beneficiaries are less likely to
PHP189 AugMenTing THe regulATory requireMenTs of MediCATion THerAPy MAnAgeMenT To iMProve ProgrAM effiCienCy And ouTCoMes
